APC and TP53 doubly mutated tumors showed the greatest sensitivity to EGFR-inhibitors, while mutated APC tumors also possessed a significant sensitivity compared to wild-type APC tumors, increasing the potential for wider clinical implementation in metastatic colorectal cancer therapy (Yang et al., 2019). The gene discussed is EGFR; the disease is metastatic colorectal cancer.